Amissa Launches AI Menopause Platform
NIH-backed startup Amissa has launched an AI-powered platform to address the estimated $24.8 billion data gap in menopause care. The platform leverages both structured and unstructured symptom data to provide guidance for clinicians and consumers. Early adoption by clinicians signals a move toward AI-driven support for previously overlooked health conditions.
- The global menopause market was valued at approximately $17.8 billion in 2024 and is projected to reach over $24.3 billion by 2030, driven by an increasing awareness of wellness needs for aging women. In the U.S. alone, around 6,000 women enter menopause daily. - Amissa's platform integrates data from patient questionnaires, self-tracked symptoms, and wearables like Apple Watch, Oura, and Whoop to create a unified clinical record for providers. This use of person-generated health data is a key trend, allowing for continuous monitoring rather than relying on patient recall during appointments. - The company is a recipient of the NIH's Small Business Innovation Research grant and differentiates itself as a B2B platform focused on clinical connectivity, unlike direct-to-consumer virtual providers like Midi Health or Gennev. - For AI to be used in healthcare apps, it must comply with HIPAA's Privacy and Security Rules, which require safeguards like encryption, access controls, and a signed Business Associate Agreement (BAA) with any third-party AI vendors handling patient data. Public AI tools like the free versions of ChatGPT are not HIPAA compliant because vendors may use input data for model training. - Successful consumer health apps like Flo and Noom have leveraged data-driven personalization and psychology-based approaches to grow and retain users. Flo increased engagement by providing users with comparative cycle data, while Noom uses bite-sized daily lessons and a combination of human and AI coaching. - AI algorithms can analyze large datasets from wearables and self-reported symptoms to identify women at higher risk for menopause-related complications like osteoporosis and cardiovascular disease, enabling personalized preventive strategies. One study found AI-driven health plans reduced hot flash severity by 57%. - The Femtech market is seeing a surge in investment, with venture capital firms like RH Capital, Amboy Street Ventures, and SteelSky Ventures actively funding startups in women's health. In 2024, startups like virtual menopause clinic Midi Health raised significant Series B and C rounds. - While 64% of health tech CEOs with a successful exit are first-timers, many come from roles with significant P&L experience, such as president or general manager. Over half of global HealthTech startups are now led by serial founders, who often find it easier to secure funding.
